Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
- 2024-08-03
- RCT · n = 83
- Lipids in health and disease 23(1)
- Yufeng Jin
- Xin Wang
- Ke Chen
- Yu Chen
- Lixin Zhou
- Yupeng Zeng
- Yuqing Zhou
- Zhijun Pan
- Di Wang
- Zhongxia Li
- Yongqian Liang
- Wenhua Ling
- Dan Li
- PubMed: 39097726
- DOI: 10.1186/s12944-024-02220-y
- High evidence
- Clinical
and ApoB (-0.02 ± 0.03 vs. 0.07 ± 0.03, P = 0.023)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 103.2 mg/d